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Abstract
Background: Single nucleotide polymorphisms (SNPs) have emerged as the genetic marker of
choice for mapping disease loci and candidate gene association studies, because of their high density
and relatively even distribution in the human genomes. There is a need for systems allowing
medium multiplexing (ten to hundreds of SNPs) with high throughput, which can efficiently and
cost-effectively generate genotypes for a very large sample set (thousands of individuals). Methods
that are flexible, fast, accurate and cost-effective are urgently needed. This is also important for
those who work on high throughput genotyping in non-model systems where off-the-shelf assays
are not available and a flexible platform is needed.
Results:  We demonstrate the use of a nanofluidic Integrated Fluidic Circuit (IFC) - based
genotyping system for medium-throughput multiplexing known as the Dynamic Array, by
genotyping 994 individual human DNA samples on 47 different SNP assays, using nanoliter volumes
of reagents. Call rates of greater than 99.5% and call accuracies of greater than 99.8% were
achieved from our study, which demonstrates that this is a formidable genotyping platform. The
experimental set up is very simple, with a time-to-result for each sample of about 3 hours.
Conclusion: Our results demonstrate that the Dynamic Array is an excellent genotyping system
for medium-throughput multiplexing (30-300 SNPs), which is simple to use and combines rapid
throughput with excellent call rates, high concordance and low cost. The exceptional call rates and
call accuracy obtained may be of particular interest to those working on validation and replication
of genome- wide- association (GWA) studies.
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Background
Single nucleotide polymorphisms (SNPs) have emerged
as the genetic marker of choice for mapping disease loci
and candidate gene association studies, because of their
high density and relatively even distribution in the human
genomes [1]. Both the International Human Genome
Sequencing Project and the International HapMap
Projects have generated large amounts of data on the loca-
tion, quantity, type, and frequency of genetic variants, in
particular of SNPs, in the human genome [2-7]. The deter-
mination of genome-wide linkage disequilibrium (LD)
patterns through the HapMap project has enabled the
selection of markers for efficient genome-wide association
(GWA) studies in human samples[8]. Recent technologi-
cal advances in ultra high-throughput genotyping plat-
forms potentially permit the parallel analysis of millions
of SNPs with a significant reduction in genotyping price,
making GWA studies a reality [9-13].
The impact of this approach is readily visible, since over
296 publications have been collected in the last three
years in the National Cancer Institute (NCI)-National
Human Genome Research Institute (NHGRI)'s catalog of
published genome-wide association studies [14].
Many challenges still exist after this first wave of GWA
studies, and one of them is the validation and replication
of the positive hits from the GWA screening. A multistage
approach has been suggested to increase GWA efficiency
with proper validation steps [8]. A large number of indi-
viduals are usually required to be genotyped on a small
subset of candidates SNPs. Many SNP genotyping meth-
ods have been developed on varieties of platforms in the
past decade [15,16], with several technologies using solid-
phase-mediated detection being able to genotype thou-
sands of sites simultaneously, such as the GeneChip array
and the BeadArray [17-19]. These methods have provided
ultra multiplex and high-throughput genotyping but are
not cost effective for genotyping a large number of sam-
ples for a modest number of SNPs. Homogenous detec-
tion methods such as TaqMan®  [20] and molecular
beacon -based [21] approaches provide uniplex reactions,
and are readily applied to a large number of samples but
multiplexing may be difficult. Between these two (ultra-
high multiplexing and low/no multiplexing) methods
there is a need for systems allowing medium multiplexing
(ten to hundreds of SNPs) with high throughput, which
can efficiently and cost-effectively generate genotypes for
a very large sample set (thousands of individuals). There-
fore, alternative methods that are flexible, fast, accurate
and cost-effective are urgently needed. This is also impor-
tant for those who work on high throughput genotyping
in non-model systems where off-the-shelf assays are not
available and a flexible platform is needed.
We have developed a nanofluidic platform to meet the
needs of medium multiplex high throughput SNP geno-
typing and demonstrate call rates of >99% and accuracy
rates of >99.8% under uniform assay conditions, on
human samples.
Results and Discussion
Chip Architecture
The chip used in this study, the 48.48CS dynamic array, is
mounted on a plastic carrier with interface and contain-
ment accumulators and 48 sample inlets and 48 assay
inlets, with the dimensions of the inlets and the size of the
plate conforming to the standards set by the Society for
Biomolecular Sciences (SBS format). The chip has the
ability to test 48 samples with 48 SNP assays. These com-
bine in pair wise fashion to produce 2304 reaction cham-
bers, in a final volume of 6.75 nl (Figure 1). A similar chip
has been described previously by Spurgeon et.al (2008)
[22]. The integrated fluidic circuit (IFC) is a network of
fluid lines, NanoFlex™ valves and chambers. The
NanoFlex™ valves are made of an elastomeric material
which deflects under pressure to create a tight seal and are
used to regulate the flow of liquids in the IFC. Prior to
loading, the chip is primed using the NanoFlex™ 4-IFC
Controller which pressurizes the control lines and closes
the interface valves. Individual samples are pipetted into
the sample inlets and genotyping TaqMan® assays are
pipetted into the detector inlets. The chip is then placed
back on the NanoFlex™ 4-IFC Controller for loading and
mixing. During this process, pressure is applied to the
fluid in the sample inlets and the fluid is pushed into the
sample fluid lines. At the same time the fluid in the assay
inlets is pushed into the assay fluid lines. Mixing of the
two fluids is prevented by the closed interface valve.
This chip (Figure 1) utilizes a design known as the carry-
over slug (CS) design, providing precise metering of fluid
volumes and efficient mixing of the metered volumes. A
first solution (comprising of a specific TaqMan® assay) is
introduced into a segment of a flow channel in fluidic
communication with a reaction chamber. A second solu-
tion (the sample mix) is flowed through the segment so
that the first (assay) solution is displaced into the reaction
chamber, and a volume of the second (sample) solution
enters the chamber. The chamber is then isolated and
reactions within the chamber can be initiated by thermal
cycling. This load-mix process takes approximately 45
minutes. After loading and mixing is complete, the chip is
placed on a standalone PCR thermal cycler for PCR. The
volumes involved in performing genotyping on theBMC Genomics 2009, 10:561 http://www.biomedcentral.com/1471-2164/10/561
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Dynamic Array significantly reduces the genotyping rea-
gent consumption and labor cost (see Table 1).
Once PCR is complete, endpoint fluorescent image data is
acquired on the BioMark™ System for Genetic Analysis
and data is analyzed using the Fluidigm SNP Genotyping
Analysis software, to obtain genotype calls. Figure 2a
shows the raw image from a chip run in both FAM (exci-
tation and emission peaks at 495 and 520 nm respec-
tively) and VIC (excitation and emission peaks at 538 and
554 nm respectively) fluorescent channels. Figure 2b
shows a computer generated image of the genotype calls
for each of the 2304 reaction chambers. Each column
(vertical direction) represents data from one assay that
correlated to the SNP genotyping assay loaded from each
assayinlet.
Each row represents data from one DNA sample loaded
from each sample inlet. In brief, the genotyping software
calculates the fluorescent signals from both FAM and VIC
channels and plots each sample on a scatter plot using the
FAM relative intensity (to ROX background) on the X-axis,
and VIC relative intensity on the Y-axis. We then used a k-
means clustering algorithm based on nearest-centroid
sorting to automatically classify samples into four geno-
type groups, or three if the rare homozygous allele is not
present in a particular chip run. Figure 2c shows a geno-
typing scatter plot with genotype calls automatically
assigned by the analysis software with 4 different colors
coded, one for each genotype plus one NTC (black dots).
The software is capable of analyzing multiple chip runs
simultaneously, and up to 22 chip runs were analyzed
together in this study (Figure 2d).
Human SNP Genotyping
We utilized this nanofluidic system to genotype SNPs in
human genomic DNA samples. The DNA screened
included 905 DNA samples extracted from blood from
the Prostate, Lung, Colon, and Ovarian Cancer (PLCO)
Screening Trial [23], and 89 HapMap samples extracted
from cell lines. All samples were double-blinded, and
were genotyped on 22 dynamic arrays. Chips were ther-
mal cycled using standard conditions (see materials and
methods), and the end-point fluorescence values were
measured on the BioMark™ system. A total of 2 μl of each
DNA sample (50 ng) was used in a 5 μl sample mix to gen-
otype 47 SNP assays and one non-reagent control. Each
chip only needs a total of 96 liquid-transfer (pipetting)
steps (48 for the sample and 48 for the assay mixes),
which is considerably less pipetting than required to set
up 6 conventional 384 well plates (4608 pipetting, 2304
× samples plus 2304 × assays) with the same genotyping
output. We manually set up 8 chip runs on each working
day with a throughput of about 18,000 genotypes per day,
without using robotic stations. The endpoint genotype
data were analyzed using the Fluidigm SNP Genotyping
Analysis software (Figure 2). We achieved a call rate of
greater than 99.1% from the 994 genotyped samples on
47 SNPs. In comparison, we have also used an Applied
Biosystems 7900 HT with standard microtiter plates and
TaqMan® genotyping methodologies to genotype the 905
PLCO samples on 20 SNPs and the 89 HapMap samples
on 38 SNPs, and obtained a lower call rate at 98.5% with
almost every SNP in comparison to the results obtained
on the Fluidigm dynamic array (Figure 3a, Table 2). We
have estimated the genotyping concordance between the
results from the 48.48CS chip and the microtiter plates
run on the Applied Biosystems 7900 HT (Figure 3b) sys-
tem. Among the 20 SNPs genotyped on 905 PLCO sam-
ples, all SNPs gave ≥ 99.5% concordance, except for one
with 98.8%. Among the 89 HapMap samples genotyped
by both platforms, all SNPs except three had concordance
rates of 99% to 100% (Figure 3b).
We next estimated the genotyping accuracy after unblind-
ing the samples. The genotyping results obtained from the
89 HapMap DNA samples were compared with the corre-
sponding data in the dbSNP database http://
www.ncbi.nlm.nih.gov/projects/SNP/. We achieved a call
rate of 99.8% for all samples across 47 genotyped SNPs
(4183 genotypes) using the BioMark™ System. A total of
3950 genotypes of the tested SNPs were found in the
dbSNP database for these HapMap samples; our genotyp-
ing results matched 3943 with only 7 mismatches, result-
ing in a 99.82% concordance. Almost all of the SNPs
except for six gave 100% concordance (Figure 3b). We
also determined the reproducibility (concordance) of our
system. As mentioned earlier, some of the 905 PLCO sam-
ples had been provided in (blind) replicates. The repli-
cates comprised a total of 130 samples, and included 54
A 48.48CS dynamic array showing the position of the sample  inlets and the assay inlets Figure 1
A 48.48CS dynamic array showing the position of the 
sample inlets and the assay inlets.BMC Genomics 2009, 10:561 http://www.biomedcentral.com/1471-2164/10/561
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duplicates (108 samples), 6 triplicates (18 samples) and 1
quadruplicate (4 samples) set, resulting in 65 pair-wise
comparisons. Of the 65 pair wise comparisons 55 pairs
exhibited 100% concordance for 47 SNPs. Of the discord-
ant pairs of samples: 8 pairs had a single discordant result;
1 pair had two discordant results and 1 pair had three dis-
cordant results. Of the 47 SNP assays, 43 have no discord-
ance. Of the discordant assays: 1 assay exhibited a single
discordance; 2 assays exhibited two discordances and 2
assays exhibited four discordances. The total reproducibil-
ity rate is > 99.78%.
When analyzing the call rate sample-by-sample, we
noticed that 15 samples from the adenoma project con-
tributed to over 50% of the total no call rate (failed to
have valid genotypes). We amplified these 15 samples
using a Specific Target Amplification (STA) protocol on
the 47 targeted SNPs [24]. The amplified samples were
diluted five- fold after STA and then genotyped on
48.48CS dynamic array. Figure 4 shows the genotyping
results from both genomic and STA DNA from these 15
samples. The STA and genomic DNA were genotyped on
the same chip side-by-side. The circled data points are
from STA samples, which clearly showed much higher sig-
nal levels than the genomic DNA samples. With STA, all
15 samples except for one, had their genotype call-rate
across 47 SNPs improve significantly, with most of them
having call rates of up to 98 to 100% (Table 3). One sam-
ple could not be amplified, reflecting the possible pres-
ence of some form of PCR inhibitor in the original
sample. The overall call rate for the 994 samples improved
to 99.5% with the STA step.
Input DNA quantity affects genotyping accuracy
On the 48.48CS dynamic array, each DNA sample is dis-
tributed into 48 reaction chambers to genotype 48 SNPs.
Typically, ~2 μl of DNA sample is made up to 5 μl with
TaqMan® Mastermix and other additives (see Materials
and Methods), is loaded into the inlets of each chip, and
is distributed into 48 reaction chambers, in a final volume
of 6.5 nl per reaction chamber. When the initial number
of DNA copies are low, as a result of the reduction in over-
all volume (approximately a 1000 fold reduction), the
number of actual DNA molecules tested becomes limit-
ing. In the experiments described earlier, each 6.5 nl reac-
tion chamber contained about 25 copies of DNA
molecules, in contrast to typical microtitre plates, which
use about 500-600 fold more DNA. To evaluate the effect
that DNA copy number has on genotyping calls, we tested
three genomic DNA samples with three different geno-
types for a single SNP (rs513349). Different amounts of
DNA were loaded into Dynamic Array chips, such that the
final DNA copy number in reaction chambers ranged
from 0.9 to 90 copies of genomic equivalents. Figure 5
shows the genotyping clusters obtained with different
amounts of input DNA.
As can be seen, when 45 to 90 copies of genomic DNA are
tested, one gets excellent call rates (Table 4), with the het-
erozygotes called correctly in all cases. As the number of
copies tested decrease, the numbers of no-calls and call
errors increase. For example, when the copy number is 9
DNA molecules per reaction chamber, 22% (95% confi-
dence interval: 0.16, 0.31) of the calls in the heterozygous
cases failed to identify the correct genotype. Additionally,
as would be predicted, when single molecules are tested,
the heterozygotic calls (XY) decrease dramatically, with
the number of homozygous calls and no-calls increasing
proportionately. The tightness of the clusters (and there-
fore the call confidence) also decreases as the copy
number decreases. Finally, when the DNA copy number
averages 0.9 copies per reaction chamber, the no-call rate
increases to 40%, 58% and 32% in the case of homozy-
gotes A1A1, heterozygotes A1A2 and homozygotes A2A2,
respectively. These no-call rates are significantly higher
compared to those when the DNA copy number averages
4.5 copies per chamber (p value = 1.4E-17, 1.1E-31 and
2.3E-10, respectively). Meanwhile, the error rate of the
calls in the heterogeneous case also increases significantly
from 32% in the case of 4.5 copies per chamber to 84% in
the case of 0.9 copies per chamber (p value:1.1E-14). This
clearly shows the role that gene copy number and DNA
concentration have on genotyping call quality and could
have a significant impact on the data obtained from pre-
vious genotyping studies which have not monitored the
amount of amplifiable DNA molecules in their sample
preparation.
Table 1: Comparison of Genotyping Reagent Consumption
48.48 array 384-well plate Fold saving
Total number of reactions 2304 2304
Number of chips/plates 1 6
Volume of each reaction 6.75 nL 10 μL
2× Mastermix (μL) 120* 11520 96
10× Primer/Probe Mix (μL) 24* 2304 96
Number of pipetting steps/tips 96 4608 48
* On the Dynamic Array using 5 μL reaction mixes for 48 samples at a timeBMC Genomics 2009, 10:561 http://www.biomedcentral.com/1471-2164/10/561
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Conclusion
In the current study we demonstrate the use of a unique
nanofluidic genotyping system which is simple to use and
permits medium multiplexing (tens to hundreds of SNPs)
with high throughput, excellent call rates, call accuracy
and low cost. We have demonstrated the use of the
48.48CS dynamic array with Integrated Fluidic Circuits
(IFCs), by genotyping 994 individual human DNA sam-
ples on 47 different SNP assays, using nanoliter volumes
of reagents. Calls from our platform were validated by
SNP Genotyping data analysis Figure 2
SNP Genotyping data analysis. The Fluidigm SNP Genotyping Analysis software automatically analyzes the end-point image 
of a genotyping chip run and generates genotyping calls for each sample. (a). Raw image from a 48.48CS chip run in both FAM 
and VIC fluorescent channels. (b). The software generated call map view of the genotyping calls for each of the 2304 reaction 
chambers. (c) Software generated scatter plot for 48 samples in one SNP assay with genotype calls automatically. Four differ-
ent color coded, 3 genotypes plus negative controls (NTC, black dots) are observed (d) Genotyping scatter plot of samples 
from 22 chip runs.BMC Genomics 2009, 10:561 http://www.biomedcentral.com/1471-2164/10/561
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Table 2: Completion Rates comparing the Fluidigm platform with standard TaqMan chemistry (CGF)
Assay Fluidigm 
Completion 
Rate
95% CI 
lower
95% CI 
upper
NC G F  
Completion 
Rate
95% CI 
lower
95% CI 
upper
M Completion rate 
based on
A-050522 97.89 97.00 98.78 995 96.95 95.88 98.02 995 All Samples 
(N = M = 995)
A-050546 98.89 98.24 99.54 995 98.85 98.19 99.51 995 All Samples 
(N = M = 995)
A-051020 98.89 98.24 99.54 995 97.66 96.72 98.60 995 All Samples 
(N = M = 995)
A-048530 98.69 97.99 99.40 995 98.96 98.33 99.59 995 All Samples 
(N = M = 995)
A-051016 99.40 98.92 99.88 995 98.78 98.10 99.46 995 All Samples 
(N = M = 995)
A-028526 99.70 99.36 100.00 995 98.66 97.91 99.41 905 N = 995 Fluidigm M 
= 905 CGF (90 
HapMap excluded)
A-041985 98.29 97.49 99.10 995 98.22 97.36 99.08 905 N = 995 Fluidigm M 
= 905 CGF (90 
HapMap excluded)
A-051013 99.50 99.06 99.94 995 98.59 97.86 99.32 995 All Samples 
(N = M = 995)
A-051017 99.40 98.92 99.88 995 99.41 98.93 99.89 995 All Samples 
(N = M = 995)
A-051018 99.50 99.06 99.94 995 99.32 98.81 99.83 995 All Samples 
(N = M = 995)
A-029470 99.80 99.52 100.00 995 98.66 97.91 99.41 905 N = 995 Fluidigm M 
= 905 CGF (90 
HapMap excluded)
A-050521 99.70 99.36 100.00 995 97.55 96.59 98.51 995 All Samples 
(N = M = 995)
A-048529 99.80 99.52 100.00 995 99.25 98.71 99.79 995 All Samples 
(N = M = 995)
A-041990 99.90 99.70 100.00 995 99 98.35 99.65 905 N = 995 Fluidigm M 
= 905 CGF (90 
HapMap excluded)
001_2058 99.50 99.06 99.94 995 99 98.35 99.65 905 N = 995 Fluidigm M 
= 905 CGF (90 
HapMap excluded)
A-050301 99.50 99.06 99.94 995 99.28 98.75 99.81 995 All Samples 
(N = M = 995)
A-051015 99.80 99.52 100.00 995 99.22 98.67 99.77 995 All Samples 
(N = M = 995)
A-051019 99.50 99.06 99.94 995 98.82 98.15 99.49 995 All Samples 
(N = M = 995)
A-042514 99.30 98.78 99.82 995 99.65 99.28 100.00 995 All Samples 
(N = M = 995)
A-051014 99.90 99.70 100.00 995 99.61 99.22 100.00 995 All Samples 
(N = M = 995)
A-035643 99.60 98.29 100.00 90 N.D. N.D N.D. N.D. N = 90 Fluidigm 
HapMap
A-036266 99.70 98.57 100.00 90 N.D. N.D. N.D. N.D. N = 90 Fluidigm 
HapMap
A-048531 100.00 100.00 100.00 90 94.59 89.92 99.26 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-050302 100.00 100.00 100.00 90 87.39 80.53 94.25 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-050526 99.90 99.24 100.00 90 89.19 82.77 95.61 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-050527 100.00 100.00 100.00 90 89.19 82.77 95.61 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMapBMC Genomics 2009, 10:561 http://www.biomedcentral.com/1471-2164/10/561
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A-050528 100.00 100.00 100.00 90 90.09 83.92 96.26 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-050532 100.00 100.00 100.00 90 89.19 82.77 95.61 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-050534 100.00 100.00 100.00 90 89.19 82.77 95.61 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-050537 100.00 100.00 100.00 90 90.09 83.92 96.26 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-050540 100.00 100.00 100.00 90 90.09 83.92 96.26 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-050541 100.00 100.00 100.00 90 89.19 82.77 95.61 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-051351 100.00 100.00 100.00 90 99.1 97.15 100.00 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-051352 100.00 100.00 100.00 90 98.2 95.45 100.00 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-051353 100.00 100.00 100.00 90 98.2 95.45 100.00 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-051354 99.80 98.87 100.00 90 N.D. N.D. N.D. N.D. N = 90 Fluidigm 
HapMap
A-051355 100.00 100.00 100.00 90 99.1 97.15 100.00 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-051356 100.00 100.00 100.00 90 99.1 97.15 100.00 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-051357 100.00 100.00 100.00 90 99.1 97.15 100.00 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-051358 100.00 100.00 100.00 90 N.D. N.D. N.D. N.D. N = 90 Fluidigm 
HapMap
A-051359 100.00 100.00 100.00 90 98.2 95.45 100.00 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-051360 99.90 99.24 100.00 90 97.3 93.95 100.00 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-051361 100.00 100.00 100.00 90 98.2 95.45 100.00 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-051362 99.90 99.24 100.00 90 99.1 97.15 100.00 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-051363 100.00 100.00 100.00 90 98.2 95.45 100.00 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-051364 100.00 100.00 100.00 90 98.2 95.45 100.00 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
A-051365 100.00 100.00 100.00 90 94.59 89.92 99.26 90 N = 90 Fluidigm 
HapMap and M = 90 
CGF HapMap
Table 2: Completion Rates comparing the Fluidigm platform with standard TaqMan chemistry (CGF) (Continued)BMC Genomics 2009, 10:561 http://www.biomedcentral.com/1471-2164/10/561
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Comparison of genotyping results from 48.48CS dynamic array with microtiter plates run on Applied Biosystems 7900 HT Figure 3
Comparison of genotyping results from 48.48CS dynamic array with microtiter plates run on Applied Biosys-
tems 7900 HT. (a) Call rate comparison; (b) Concordance/Accuracy with HapMap results.BMC Genomics 2009, 10:561 http://www.biomedcentral.com/1471-2164/10/561
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selected genotyping of the same samples on the Applied
Biosystems 7900 HT, while calls from the HapMap sam-
ples were compared with results obtained by the HapMap
project.
Call rates of greater than 99.5% and call accuracy >99.8%
were achieved from our study, which demonstrates that
this is a formidable genotyping platform. The experimen-
tal set up is very simple, with a time-to-result for each sam-
ple of about 3 hours. In comparison, similar products by
Illumina (GoldenGate ® Assay) and Sequenom (iPlex™
assay) have reported call rates of only 99% and 90-95%
respectively, take days (Illumina), not hours to obtain
results, and have a complicated workflow(both Illumina
and Sequenom) [25,26]. While we use TaqMan assays in
our approach, the reduced reaction volume (6.5 nl) ena-
bles the cost of genotyping to be only 5 cents per data
point, which compares very favorably with other plat-
forms, which cost more, typically ranging by twice to an
order of magnitude. While a detailed cost comparison is
beyond the scope of this manuscript, it has been docu-
mented in other publications [27]. Thus, our approach
has higher call rates, a significantly faster throughput, an
easier workflow and lower cost than other medium
throughput genotyping systems. The development of this
nanofluidic genotyping system enhances the ability to
screen mid-range numbers of SNPs across hundreds to
thousands of samples.
Methods
Instrumentation and Nanofluidic Chips
The nanofluidic chip used in this study, 48.48CS dynamic
array chips, the NanoFlex™ 4-IFC Controller and the
BioMark™ Real-Time PCR System are manufactured by
Fluidigm Corporation. The Nanoflex™ 4-IFC Controller
utilizes pressure to control the valves in the chips and load
samples and genotyping assay reagents into the reaction
chambers. The BioMark system can be used to thermal
cycle these nanofluidic chips and image the data in real
time [22], and can also be used as an endpoint image
reader. STA reactions were done in a GeneAmp PCR Sys-
tem 9700 from Applied Biosystems.
TaqMan® SNP Genotyping
For SNP genotyping on the dynamic array chips, a 5 μl
sample mix was prepared for each sample containing 1×
TaqMan® Universal Master Mix (Applied Biosystems, Fos-
ter City, CA), 1 × GT Sample Loading Reagent (Fluidigm
PN 85000741), 0.05 units/μl additional Taq-Gold
polymerase (Applied Biosystems) and either 50~60 ng of
genomic DNA, or diluted pre-amplified DNA. The Taq-
Man® genotyping assays at 40 × were mixed with 1/2 vol-
ume of Dynamic Array (DA) assay loading reagent
(Fluidigm PN 85000736) and 1/20 volume of 50 × ROX
(Invitrogen) to make 10 × assay mixes (9 μM primers and
2 μM probe). Prior to loading the samples and assay mixes
into the inlets, the chip was primed in the NanoFlex™ 4-
IFC Controller. The 5 μl of sample mixes prepared as
described were then loaded into each sample inlet of the
dynamic array chip and 4 μl of 10 × genotyping assay
mixes were loaded into assay inlets. The chip was then
placed on the NanoFlex™ 4-IFC Controller for loading and
mixing. After approximately 45 minutes the chip was
ready for thermal cycling and detection of the reaction
products on the modified stand-alone thermal cyclers.
PCR was performed with an initial 2 min at 50°C and 10
min at 95°C, followed by 40 cycles of a 2-step amplifica-
tion profile consisting of 15 s at 95°C for denaturation
and 1 min at 60°C for annealing and extension. The end-
point fluorescent image data were acquired on the
BioMark™ Real-Time PCR System. Data was analyzed
Table 3: STA improves the call rate of DNA samples
Sample Name No Call XX XY YY Grand Total Call rate w/o STA Call rate with STA
SB303208 6 9 19 13 47 87.2% 100.0%
SB303368 34 9 1 3 47 27.7% 97.9%
SB303440 12 12 11 12 47 74.5% 100.0%
SB303578 15 11 13 8 47 68.1% 97.9%
SB303579 16 10 11 10 47 66.0% 95.7%
SB303632 7 15 12 13 47 85.1% 97.9%
SB303637 5 16 15 11 47 89.4% 100.0%
SB303638 5 16 16 10 47 89.4% 89.4% *
SB303655 41 2 2 2 47 12.8% 89.4%
SB303880 10 1 33 3 47 78.7% 100.0%
SB303913 11 10 13 13 47 76.6% 100.0%
SB303918 5 16 16 10 47 89.4% 100.0%
SB303919 15 16 7 9 47 68.1% 100.0%
SB304064 23 12 3 9 47 51.1% 100.0%
SB304072 6 16 13 12 47 87.2% 100.0%
* This sample failed STA, because of possible PCR inhibition.BMC Genomics 2009, 10:561 http://www.biomedcentral.com/1471-2164/10/561
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using the Fluidigm SNP Genotyping Analysis software to
obtain genotype calls.
Human SNP Genotyping
We have used 48.48CS dynamic array chips to genotype
995 human DNA samples across 47 different SNP assays.
A total of 89 HapMap Caucasian Trio samples and 905
Case: Controls from a Prostate, Lung, Colon, and Ovarian
(PLCO) Cancer Screening Trial sponsored by the NCI,
were genotyped in a blinded mode. A total of 2 μl of 25
ng/μl DNA from each sample were used in each sample
reaction mix to genotype the 47 SNPs. These 995 samples
were genotyped on 22 dynamic array chips. The reagents
were prepared manually without using an automated
Comparison of genotyping calls from the same sets of 15 samples that were either genotyped directly, or after the STA step Figure 4
Comparison of genotyping calls from the same sets of 15 samples that were either genotyped directly, or after 
the STA step. The circled dots are data points generated from the STA samples.BMC Genomics 2009, 10:561 http://www.biomedcentral.com/1471-2164/10/561
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Comparison of genotype call accuracy related to input DNA copy number Figure 5
Comparison of genotype call accuracy related to input DNA copy number. Three genomic DNA samples carrying 
different genotypes with varied input amount were genotyped on SNP rs513349. The scatter plots of different DNA copy 
number ends in each reaction chambers are shown, (a) 0.9 copies; (b) 4.5 copies; (c) 9 copies; (d) 45 copies; (e) 90 copies.BMC Genomics 2009, 10:561 http://www.biomedcentral.com/1471-2164/10/561
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robotic station. We used 3 stand-alone thermal cyclers
and one BioMark™ Real-Time PCR System to perform PCR
and read the chip runs on the single BioMark system after
40 cycles. Eight chips were run on each working day with
a throughput of about 18,000 genotypes per day (48 sam-
ples × 47 assays × 8 chips). The endpoint chip reading was
analyzed using the Fluidigm SNP Genotyping Analysis
software.
Specific Target Amplification
When either the quantity and/or the quality of the input
DNA is not ideal, a Specific Target Amplification (STA)
was performed to enrich targeted SNP sequences. The 40×
TaqMan® assays (with 36 μM primers) of targeted SNPs
were mixed and diluted with DNA-free water to prepare
0.2 × assay mix (180 nM primers). STA was performed on
a GeneAmp PCR 9700 system (Applied Biosystems, Foster
City, CA) in a 5 μl reaction containing 2.5 μl of 2× Taq-
Man® PreAmp master mix (Applied Biosystems, Foster
City, CA), 1.25 μl of 0.2× of assay mix prepared as
described and 1.25 μl of the DNA sample. Thermocycling
conditions were 10 min at 95°C, followed by 14 cycles of
a 2-step amplification profile of 15 sec at 95°C and 2 min
at 60°C.
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